- Roche (RHHBY, Financial) has received CE Mark approval for its Chest Pain Triage algorithm, enhancing detection of Acute Coronary Syndrome (ACS).
- The algorithm can potentially reduce Emergency Department visit times by over three hours.
- Currently available in Europe, the Middle East, and Asia, with future plans for U.S. availability.
Roche (RHHBY), in collaboration with Universitätsklinikum Heidelberg, has received CE Mark approval for its innovative Chest Pain Triage algorithm, part of the navify® Algorithm Suite. Designed to enhance the detection of Acute Coronary Syndrome (ACS), the algorithm aims to differentiate effectively between cardiac and non-cardiac chest pain in emergency departments using high-sensitivity cardiac troponin testing and guidelines from the European Society of Cardiology (ESC).
The algorithm offers a significant advantage by potentially reducing Emergency Department visit times by over three hours. It provides medical professionals with Rule-In, Rule-Out, or Observe recommendations and automatically selects the appropriate ESC pathway based on blood sample timing, integrating seamlessly with existing emergency department workflows through Electronic Health Records (EHR) and Lab Information Systems (LIS).
Roche's innovative solution is currently available in Europe, the Middle East, and Asia, with plans to extend its availability to the United States. This development aligns with Roche's commitment to improving cardiovascular care, aiming to reduce unnecessary hospital admissions, associated costs, and expedite the treatment process for true ACS cases through rapid assessments.
The navify Algorithm Suite, a cloud-based platform, facilitates integration with hospital systems, providing a robust digital infrastructure for the healthcare community. This initiative is part of Roche's ongoing efforts to advance healthcare delivery through digital solutions.
